{
    "ticker": "MTNB",
    "name": "Matinas BioPharma Holdings, Inc.",
    "description": "Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with unmet medical needs. Founded in 2014 and headquartered in Bedminster, New Jersey, Matinas leverages its proprietary lipid nano-crystal (LNC) technology platform to enhance the delivery of therapeutic compounds. This technology allows for improved bioavailability and absorption of drugs, particularly in the treatment of infectious diseases and other serious health conditions. The company's lead product candidate, MAT2501, is an oral formulation of the antibiotic amikacin, specifically targeting patients with cystic fibrosis and other serious infections. Matinas is also advancing several other candidates in its pipeline, focusing on areas such as antifungal therapies and rare diseases. With a commitment to innovation and patient-centric solutions, Matinas BioPharma aims to change the landscape of drug delivery and improve treatment outcomes for patients globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bedminster, New Jersey, USA",
    "founded": "2014",
    "website": "https://www.matinasbiopharma.com",
    "ceo": "Gerald J. Cosgrove",
    "social_media": {
        "twitter": "https://twitter.com/MatinasBio",
        "linkedin": "https://www.linkedin.com/company/matinas-biopharma-holdings-inc"
    },
    "investor_relations": "https://investors.matinasbiopharma.com",
    "key_executives": [
        {
            "name": "Gerald J. Cosgrove",
            "position": "CEO"
        },
        {
            "name": "Andrew D. Dorr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "MAT2501"
            ]
        }
    ],
    "seo": {
        "meta_title": "Matinas BioPharma Holdings, Inc. | Innovative Drug Delivery Solutions",
        "meta_description": "Explore Matinas BioPharma Holdings, Inc., a leader in drug delivery technology. Learn about their innovative therapies aimed at addressing critical medical needs.",
        "keywords": [
            "Matinas BioPharma",
            "Drug Delivery",
            "Biotechnology",
            "Pharmaceuticals",
            "MAT2501"
        ]
    },
    "faq": [
        {
            "question": "What does Matinas BioPharma specialize in?",
            "answer": "Matinas BioPharma specializes in developing innovative drug delivery solutions using its proprietary lipid nano-crystal technology."
        },
        {
            "question": "What is the lead product candidate of Matinas?",
            "answer": "The lead product candidate is MAT2501, an oral formulation of amikacin aimed at treating cystic fibrosis."
        },
        {
            "question": "Where is Matinas BioPharma located?",
            "answer": "Matinas BioPharma is headquartered in Bedminster, New Jersey, USA."
        },
        {
            "question": "When was Matinas BioPharma founded?",
            "answer": "Matinas BioPharma was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "VRTX"
    ],
    "related_stocks": [
        "BMY",
        "ABBV",
        "MRNA",
        "JNJ"
    ]
}